(5-Cyclohexyl-1-{[isopropyl-(4-methoxy-phenyl)-carbamoyl]-methyl}-2-oxo-4-oxy-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-carbamic acid benzyl ester | 173459-69-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯二氮卓类
• 英文名称: (5-Cyclohexyl-1-{[isopropyl-(4-methoxy-phenyl)-carbamoyl]-methyl}-2-oxo-4-oxy-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-carbamic acid benzyl ester
• 英文别名: benzyl N-[5-cyclohexyl-1-[2-(4-methoxy-N-propan-2-ylanilino)-2-oxoethyl]-4-oxido-2-oxo-3H-1,4-benzodiazepin-4-ium-3-yl]carbamate
• CAS: 173459-69-3
• 化学式: C₃₅H₄₀N₄O₆
• 分子量: 612.726
• InChiKey: HEZMPRRHXBPYOH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.7
• 重原子数：
  45
• 可旋转键数：
  10
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.37
• 拓扑面积：
  117
• 氢给体数：
  1
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  (5-Cyclohexyl-1-{[isopropyl-(4-methoxy-phenyl)-carbamoyl]-methyl}-2-oxo-4-oxy-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-carbamic acid benzyl ester 在 钯 氢气 作用下， 以 乙醇 为溶剂， 生成 2-(3-Amino-5-cyclohexyl-2-oxo-4-oxy-2,3-dihydro-benzo[e][1,4]diazepin-1-yl)-N-isopropyl-N-(4-methoxy-phenyl)-acetamide
  参考文献：
  名称：

  1,4-Benzodiazepine Peripheral Cholecystokinin (CCK-A) Receptor Agonists

  摘要：

  A series of 1,4-benzodiazepines, N-1-substituted with an N-lisopropyl-N-phenvlacetamide moiety, was synthesized and screened fur CCK-A agonist activity. In vitro agonist activity on isolated guinea Fig gallbladder along with in vivo induction of satiety following intraperitoneal administration in a rat feeding assay was demonstrated. (C) 2001 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(01)00164-0
• 作为产物：
  描述：

  2-bromo-N-isopropyl-N-(4-methoxy-phenyl)-acetamide 在 sodium hydride 、 间氯过氧苯甲酸 作用下， 以 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 生成 (5-Cyclohexyl-1-{[isopropyl-(4-methoxy-phenyl)-carbamoyl]-methyl}-2-oxo-4-oxy-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-carbamic acid benzyl ester
  参考文献：
  名称：

  1,4-Benzodiazepine Peripheral Cholecystokinin (CCK-A) Receptor Agonists

  摘要：

  A series of 1,4-benzodiazepines, N-1-substituted with an N-lisopropyl-N-phenvlacetamide moiety, was synthesized and screened fur CCK-A agonist activity. In vitro agonist activity on isolated guinea Fig gallbladder along with in vivo induction of satiety following intraperitoneal administration in a rat feeding assay was demonstrated. (C) 2001 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(01)00164-0

文献信息

• A METHOD OF INDUCING CHOLECYSTOKININ AGONIST ACTIVITY USING 1,4-BENZODIAZEPINE COMPOUNDS
  申请人：GLAXO WELLCOME INC.

  公开号：EP0755394A1

  公开（公告）日：1997-01-29
• [EN] A METHOD OF INDUCING CHOLECYSTOKININ AGONIST ACTIVITY USING 1,4-BENZODIAZEPINE COMPOUNDS<br/>[FR] PROCEDE D'INDUCTION D'UNE ACTIVITE AGONISTE DE LA CHOLECYSTOKININE A L'AIDE DE COMPOSES 1,4-BENZODIAZEPINES
  申请人：GLAXO WELLCOME INC.

  公开号：WO1995028399A1

  公开（公告）日：1995-10-26

  (EN) A method of inducing a Cholescystokinin-A receptor agonist response in a mammal by administering a compound of formula (I), where R1 is C1-C6alkyl, C3-6cycloalkyl, phenyl, or substituted phenyl; R2 is C3-6alkyl, C3-6cycloalkyl, C3-6alkenyl, benzyl, phenylC1-3alkyl or substituted phenyl; or NR1R2 together form 1,2,3,4-tetrahydroquinoline, 1,2,3,4-tetrahydroquinoline or benzazepine mono-, di-, or trisubstituted independently with C1-6alkyl, C1-6alkoxy or halogen substituents; n is an integer selected from the group consisting of 0, 1, 2 or 3; p is the integer 0 or 1; q is the integer 0 or 1; r is the integer 0 or 1, provided that when q is 0 then r is 0; R3, R4, R5 and R8 are selected from a variety of substituents; X is nitrogen, nitroso or R8; m is an integer selected from the group consisting of 0, 1, 2 or 3; Y and Z are hydrogen or halogen, novel intermediates, a pharmaceutical composition for treating obesity, gall bladder stasis, disorders of pancreatic secretion, methods for such treatment and processes for preparing compounds of formula (I).(FR) Procédé d'induction d'une réponse agoniste du récepteur de la cholécystokinine-A chez un mammifère par administration d'un composé de la formule (I) dans laquelle R1 représente alcoyle C1-C6, cycloalcoyle C3-6, phényle ou phényle substitué; R2 représente alcoyle C3-6, cycloalcoyle C3-6, alcényle C3-6, benzyle, phényle alcoyle C1-3 ou phényle substitué; NR1R2 forment ensemble 1,2,3,4-tétrahydroquinoline, 1,2,3,4-tétrahydroquinoline ou benzazépine mono, di ou trisubstituée indépendamment par les substituants alcoyle C1-6, alcoxy C1-6 ou halogène; n est un nombre entier valant 0, 1, 2 ou 3; p est un nombre entier valant 0 ou 1; q est un nombre entier valant 0 ou 1; r est un nombre entier valant 0 ou 1, à condition que lorsque q vaut 0, r vaille 0; R3, R4, R5 et R8 sont choisis parmi plusieurs substituants; X représente azote, nitroso ou R8; m est un nombre entier choisi parmi 0, 1, 2 ou 3; Y et Z représentent hydrogène ou halogène; l'invention concerne également de nouveaux intermédiaires des composés de la formule (I), une composition pharmaceutique destinée à traiter l'obésité, la stase de la vésicule biliaire, les troubles de la sécrétion pancréatique; l'invention concerne encore des méthodes de traitement de ces affections ainsi que des procédés de préparation desdits composés.
• 1,4-Benzodiazepine Peripheral Cholecystokinin (CCK-A) Receptor Agonists
  作者：Ronald G Sherrill、Judd M Berman、Lawrence Birkemo、Dallas K Croom、Milana Dezube、Gregory N Ervin、Mary K Grizzle、Michael K James、Michael F Johnson、Kennedy L Queen、Thomas J Rimele、Frank Vanmiddlesworth、Elizabeth E Sugg

  DOI：10.1016/s0960-894x(01)00164-0

  日期：2001.5

  A series of 1,4-benzodiazepines, N-1-substituted with an N-lisopropyl-N-phenvlacetamide moiety, was synthesized and screened fur CCK-A agonist activity. In vitro agonist activity on isolated guinea Fig gallbladder along with in vivo induction of satiety following intraperitoneal administration in a rat feeding assay was demonstrated. (C) 2001 Elsevier Science Ltd. All rights reserved.